Back to today’s briefing

Story perspectives

NHS to Provide Semaglutide to 1.2 Million at Heart Risk

4/1/2026

26 4 Full Breakdown

Summary

Story summary

The National Health Service (NHS) will offer semaglutide, branded Wegovy, to over 1.2 million people in England at risk of heart events.
National Institute for Health and Care Excellence (NICE) guidance says the drug reduces major cardiovascular events by 20% before weight loss.
Eligibility includes a body mass index of 27 or higher and a history of heart issues, with rollout this summer amid debate over side effects and costs.

1 of 1

Story summary

The National Health Service (NHS) will offer semaglutide, branded Wegovy, to over 1.2 million people in England at risk of heart events.
National Institute for Health and Care Excellence (NICE) guidance says the drug reduces major cardiovascular events by 20% before weight loss.
Eligibility includes a body mass index of 27 or higher and a history of heart issues, with rollout this summer amid debate over side effects and costs.